logo-loader
viewAstraZeneca

AstraZeneca suffers clinical setback

Its drug targeting people with chronic obstructive pulmonary disease failed to make a statistically meaningful difference

screen saying "clinical trial"
Results from a second phase III study are expected later this quarter

AstraZeneca PLC (LON:AZN) has received another clinical setback. 

Top-line data of a phase III trial of its drug Fasenra for people with chronic obstructive pulmonary disease failed to show a statistically meaningful reduction of what it called 'exacerbations' in patients with the ailment.

Last month, the company announced mixed data from its study of its treatment Imfinzi used in harness with a currently-available medication, tremelimumab, for patients with lung cancer.

Mixed data from lung cancer drug 

It failed to improve the survival chances of sufferers taking it as a third-line treatment. This is a hard to treat group where the outlook is bleak, and analysts said there were no surprises there.

However, a sub-study that assessed Imfinzi on its own measured it against a group of PD-L1-positive patients receiving chemo showed it made “clinically meaningful” difference.

The big read-out for Imfinzi comes later this year when the results of from a further phase III trial are released. This consists of a group of PD-L1-positive patients taking the drug for the first time in combination with tremelimumab.

Returning to Fasenra, results from a second phase III study are expected later this quarter.

  

 

 

Quick facts: AstraZeneca

Price: 8470 GBX

LSE:AZN
Market: LSE
Market Cap: £111.15 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpha Growth PLC using experienced team to start Alpha Growth and Income...

Alpha Growth PLC (LON: ALGW) CEO Gobind Sahney joined Steve Darling from Proactive to discuss the fund called Alpha Growth and Income fund or AGI. This funds prospective client are family offices, pension funds, and other institutions that still wish to receive some income but also want their...

2 days ago

2 min read